EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know

Alexandre Teboul iD, Laurent Arnaud, François Chasset

The Journal of Dermatology · 2024

DOI: 10.1111/1346-8138.17177 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Dermatology, 2024. Verfasst von Alexandre Teboul und 2 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology and Allergology Department, Faculty of Medicine, Tenon Hospital, Sorbonne University, Paris, France. Hauptthemen laut MEDLINE: Antimalarials, Lupus Erythematosus, Cutaneous, Hydroxychloroquine. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antimalarials (AMs), particularly hydroxychloroquine (HCQ) and chloroquine (CQ), are the cornerstone of the treatment for both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). HCQ and CQ are recommended as first‐line oral agents in all CLE guidelines. Initially thought to have potential therapeutic effects against COVID‐19, HCQ has drawn significant attention in recent years, highlighting concerns over its potential toxicity among patients and physicians. This review aims to consolidate current evidence on the efficacy of AMs in CLE. Our focus will be on optimizing therapeutic strategies, such as switching from HCQ to CQ, adding quinacrine to either HCQ or CQ, or adjusting HCQ dose based on blood concentration. Additionally, we will explore the potential for HCQ dose reduction or discontinuation in cases of CLE or SLE remission. Our review will focus on the existing evidence regarding adverse events linked to AM usage, with a specific emphasis on severe events and those of particular interest to dermatologists. Last, we will discuss the optimal HCQ dose and the balance between preventing CLE or SLE flares and minimizing toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AntimalarialsLupus Erythematosus, CutaneousHydroxychloroquineHumansChloroquineQuinacrineLupus Erythematosus, Systemic

Stichwörter der Autor:innen

antimalarialscutaneous lupus erythematosushydroxychloroquinelupus

Substanzen

AntimalarialsHydroxychloroquineChloroquineQuinacrine

Autor:innen und Institutionen

  • Dermatology and Allergology Department, Faculty of Medicine, Tenon Hospital, Sorbonne University, Paris, France.
  • Department of Rheumatology, National Reference Center for Autoimmune diseases (RESO), Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, INSERM UMR-S 1109, Strasbourg, France.
  • INSERM U1135, CIMI, Paris, France.

ORCID-Profile: Alexandre Teboul

Zitieren

APA

Teboul, A., Arnaud, L., & Chasset, F. (2024). Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know. The Journal of Dermatology. https://doi.org/10.1111/1346-8138.17177

Vancouver

Teboul A, Arnaud L, Chasset F. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17177

BibTeX
@article{Teboul2024,
  author = {Teboul, Alexandre and Arnaud, Laurent and Chasset, François},
  title = {Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know},
  journal = {The Journal of Dermatology},
  year = {2024},
  doi = {10.1111/1346-8138.17177}
}
Kostenlos starten →